Valuation: Entrada Therapeutics, Inc.

Market Cap 228M 200M 185M 170M 321M 22.03B 326M 2.21B 868M 10.78B 858M 839M 37.14B P/E 2026 *
-1.57x
P/E 2027 * -1.67x
Enterprise Value 135M 118M 109M 101M 190M 13.01B 193M 1.31B 513M 6.37B 507M 496M 21.94B EV / Sales 2026 *
9x
EV / Sales 2027 * -3.45x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day-7.98%
1 week-3.94%
Current month-13.86%
1 month-10.58%
3 months-53.24%
6 months-40.30%
Current year-38.33%
1 week 6.29
Extreme 6.29
7.13
1 month 6.29
Extreme 6.29
8.1
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 67 01/12/2020
Director/Board Member 66 04/05/2021
Director/Board Member 59 01/09/2023
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Chairman

19,000 0.0489%
10/06/26 Free

Director

19,000 0.0489%
10/06/26 Free

Director

19,000 0.0489%
Change 5-day change 1-year change 3-year change Capi.($)
-7.98%-3.94%+1.28%-63.92% 248M
+0.21%-0.79%+53.17%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-1.20%-1.94%+4.35%+402.68% 23.48B
+0.74%+2.32%-16.23%-14.44% 23.13B
+3.46%+2.52%+34.01%-5.41% 19.36B
-1.18%-2.97%+30.12%-33.30% 17.56B
-1.67%-6.00%+163.95%+284.69% 15.2B
+3.62%0.00%+29.70%+643.91% 14.83B
-0.70%-0.91%+24.87%+179.47% 14.06B
Average +0.07%-1.83%+37.56%+153.41% 23.38B
Weighted average by Cap. +1.47%-1.50%+41.42%+137.85%

Financials

2026 *2027 *
Net sales 14.99M 13.14M 12.14M 11.17M 21.07M 1.45B 21.41M 145M 56.92M 707M 56.28M 55.06M 2.44B 29.81M 26.13M 24.15M 22.21M 41.91M 2.87B 42.58M 289M 113M 1.41B 112M 109M 4.85B
Net income -176M -154M -142M -131M -247M -16.96B -251M -1.7B -668M -8.3B -660M -646M -28.58B -188M -164M -152M -140M -264M -18.09B -268M -1.82B -712M -8.85B -704M -689M -30.49B
Net Debt -93.49M -81.94M -75.74M -69.66M -131M -9.02B -134M -906M -355M -4.41B -351M -343M -15.2B -331M -291M -269M -247M -466M -31.96B -473M -3.21B -1.26B -15.64B -1.24B -1.22B -53.88B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
20/07/26 $6.340 -7.98% 371,531
17/07/26 $6.890 +0.29% 378,187
16/07/26 $6.870 -3.38% 726,508
15/07/26 $7.110 +4.56% 282,714
14/07/26 $6.800 +3.03% 245,939
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.340USD
Average target price
18.75USD
Spread / Average Target
+195.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock